| Structural highlights
Publication Abstract from PubMed
Starting from thienobenzopyran HTS hit 1, co-crystallization, molecular modeling and metabolic analysis were used to design potent and metabolically stable inhibitors of PI3-kinase. Compound 15 demonstrated PI3K pathway suppression in a mouse MCF7 xenograft model.
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.,Staben ST, Siu M, Goldsmith R, Olivero AG, Do S, Burdick DJ, Heffron TP, Dotson J, Sutherlin DP, Zhu BY, Tsui V, Le H, Lee L, Lesnick J, Lewis C, Murray JM, Nonomiya J, Pang J, Prior WW, Salphati L, Rouge L, Sampath D, Sideris S, Wiesmann C, Wu P Bioorg Med Chem Lett. 2011 Jul 1;21(13):4054-8. Epub 2011 May 13. PMID:21636270[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Staben ST, Siu M, Goldsmith R, Olivero AG, Do S, Burdick DJ, Heffron TP, Dotson J, Sutherlin DP, Zhu BY, Tsui V, Le H, Lee L, Lesnick J, Lewis C, Murray JM, Nonomiya J, Pang J, Prior WW, Salphati L, Rouge L, Sampath D, Sideris S, Wiesmann C, Wu P. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4054-8. Epub 2011 May 13. PMID:21636270 doi:10.1016/j.bmcl.2011.04.124
|
